About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Novartis said its Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint; video hand-opening time (vHOT) showed no statistically significant improvement versus placebo. The company reported signal

2026-09-08

Novartis said its Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint; video hand-opening time (vHOT) showed no statistically significant improvement versus placebo. The company reported signals of clinical activity in secondary and exploratory analyzes and said safety was overall consistent with prior data. Novartis will analyze the full dataset and consult regulators to determine next steps.

Other News
2026-09-07

Since 2026, technology and semiconductors have been significant drivers of upward revisions to global earnings forecasts, with AI capital expenditures and equity investment returns providing substantial support. However, Goldman Sachs points out that

Since 2026, technology and semiconductors have been significant drivers of upward revisions to global earnings forecasts, with AI capital expenditures and equity investment returns providing substantial support. However, Goldman Sachs points out that investors are increasingly reluctant to pay higher valuations for such more cyclical earnings, and rising leverage in the AI industry chain and persistently high long-term interest rates are also exerting downward pressure. Goldman Sachs still believes there is room for upward revisions to AI capital expenditures, and the situation of computing power demand exceeding supply may continue until 2028. Going forward, the focus will be on AI spending, investment returns, and the competitive landscape. (The above views are from a Goldman Sachs report dated September 6th.)
2026-09-07

Panama Canal administrator Ilya Espino de Marotta warned drought could force further reductions in daily transits to as low as 27 ships in coming months, below the current constrained level of 32. The potential cut is based on Panama Canal Authority

Panama Canal administrator Ilya Espino de Marotta warned drought could force further reductions in daily transits to as low as 27 ships in coming months, below the current constrained level of 32. The potential cut is based on Panama Canal Authority simulations using 1997 (the driest year on record) rainfall patterns and described as a "worst-case" scenario; climate change is shortening the return period for severe low-water events to roughly every three years. The canal, which handles more than 3% of global trade, saw transit demand surge earlier this year amid Middle East tensions, pushing daily usage above its typical 36 ships (spikes to about 40) and raising passage costs via the authority's daily auction. Authorities reduced daily transits to 32 from mid‑September to avoid stricter limits during the Dec–Apr dry season; a further cut toward 27 would intensify pressure on global shipping capacity and freight costs already strained by recent geopolitical disruptions.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.